Affymax
Affymax is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Affymax.
Affymax is a company.
Key people at Affymax.
Key people at Affymax.
Affymax, Inc. is a biopharmaceutical company originally focused on developing novel drugs for serious and life-threatening conditions, particularly in nephrology and specialty care sectors.[1][2][3] Founded in 2001, it raised $100M in venture funding but now has no significant operations, with minimal revenue ($42k TTM), a tiny market cap (~$60k), and only 2-4 employees; its stock (OTCMKTS: AFFY) trades at $0.0008 and has underperformed biotech peers and the market.[1][2][3][4]
The company previously advanced peptide-based therapeutics, including patents for erythropoietin receptor-binding peptides, but ceased active drug development years ago, marking stagnant growth with its last funding round ($60M) over 20 years ago.[1]
Affymax was founded in 2001 in Palo Alto, California, initially headquartered at 4001/4015 Miranda Avenue, with a focus on innovative biopharmaceuticals for nephrology and beyond.[1] It attracted investors like Sprout Group, Apax Partners, MPM BioImpact, Bear Stearns, and Merlin Biomed Group, raising $100M across rounds, including an unattributed VC-II stage.[1]
The company filed 16 patents, such as novel peptides for erythropoietin receptor binding granted in 2014, signaling early traction in anemia and related treatments.[1] By the 2010s, it shifted to New York (630 Fifth Avenue), but operations dwindled; today, leadership includes CEO Jonathan M. Couchman, CFO Mark G. Thompson, and VP Tracy J. Dunn.[2][4]
Affymax rode the early 2000s biotech boom in peptide therapeutics and nephrology, aligning with rising demand for anemia treatments amid chronic kidney disease prevalence.[1] Its timing capitalized on VC interest in novel biologics before regulatory hurdles intensified, influencing the ecosystem through patents that may inform current EPO receptor research.[1]
Market forces like stringent FDA approvals and competition from established players (e.g., Amgen) contributed to its decline, exemplifying biotech risks; today, it highlights consolidation trends where smaller firms pivot to IP monetization rather than operations.[2][3]
With no active drug development and negligible operations, Affymax's trajectory points to dormancy or potential acquisition for its patent portfolio amid ongoing biotech interest in nephrology peptides.[1][3] Trends like AI-driven drug discovery and gene therapies may indirectly value its legacy IP, but stock volatility and underperformance suggest limited upside without catalysts.[2][3]
Its story underscores biotech volatility—from VC darling to micro-cap shell—tying back to a cautionary tale for investors eyeing high-risk therapeutics.
